目的 探究愈风宁心滴丸联合单硝酸异山梨酯-治疗冠心病心绞痛的临床效果。方法 选取2020年1月—2022年12月于北京市隆福医院进行治疗的130例冠心病心绞痛患者进行回顾性研究，按照不同治疗方案分为对照组和治疗组，每组各65例。对照组患者饭后温水吞服单硝酸异山梨酯片，1片/次，2次/d。治疗组患者除使用单硝酸异山梨酯片外，还口服愈风宁心滴丸，12丸/次，3次/d，单硝酸异山梨酯片用法用量与对照组一致。两组均连续治疗8周。观察两组的临床疗效和心绞痛症状改善情况，比较两组心功能指标、血管内皮功能指标、氧化应激指标和炎症反应指标。结果 治疗后，治疗组总有效率是95.38%，显著高于对照组的84.62%，具有统计学差异（P＜0.05）。治疗后，两组心绞痛发作次数、疼痛评分均显著降低，而6 min步行距离（6MWD）显著增加（P＜0.05）；治疗后，治疗组心绞痛发作次数、疼痛评分低于对照组，6WMD水平高于对照组（P＜0.05）。治疗后，两组心排血量（CO）、左心室射血分数（EF）水平显著升高（P＜0.05）；治疗后，治疗组CO、EF水平高于对照组（P＜0.05）。治疗后，两组内皮细胞特异性分子-1（ESM-1）、血管紧张素II（AngII）水平较同组治疗前显著降低，而一氧化氮合酶（NOS）水平高于治疗前（P＜0.05）；治疗后，治疗组ESM-1、AngII水平低于对照组，NOS水平高于对照组（P＜0.05）。治疗后，两组总抗氧化能力（TAOC）、晚期糖基化终产物（AGEs）、淀粉样蛋白A（SAA）、白细胞介素-13（IL-13）水平较同组治疗前显著降低（P＜0.05）；治疗后，治疗组TAOC、AGEs、SAA、IL-13水平低于对照组（P＜0.05）。结论 愈风宁心滴丸联合单硝酸异山梨酯-治疗冠心病心绞痛可明显改善患者心绞痛症状，改善心功能及内皮功能，减轻氧化应激、炎症反应，临床疗效较理想。

Objective To explore the clinical effect of Yufeng Ningxin Dripping Pills combined with isosorbide mononitrate in treatment of angina pectoris. Methods A retrospective study was conducted on 130 patients with angina pectoris treated in Beijing Longfu Hospital from January 2020 to December 2022. They were divided into control group and treatment group according to different treatment protocols, with 65 cases in each group. Patients in control group swallowed Isosorbide Mononitrate Tablets with warm water after meals, 1 tablet/time, twice daily. In addition to Isosorbide Mononitrate Tablets, patients in treatment group were also given Yufengningxin Dropping Pills, 12 pills/time, 3 times daily. The usage and dosage of Isosorbide Mononitrate Tablets were consistent with those in control group. Both groups were treated continuously for 8 weeks. The clinical efficacy and improvement of angina pectoris symptoms in two groups were observed, and the indexes of cardiac function, vascular endothelial function, oxidative stress and inflammatory response were compared between two groups. Results After treatment, the total effective rate of the treatment group was 95.38%, which was significantly higher than that of the control group (84.62%), with statistical difference (P < 0.05). After treatment, the frequency of angina pectoris attack and pain score were significantly decreased in both groups, but 6MWD was significantly increased (P < 0.05). After treatment, the angina attack frequency and pain score in treatment group were lower than those in control group, and the level of 6WMD was higher than that in control group (P < 0.05). After treatment, the levels of CO and EF in two groups were significantly increased (P < 0.05). After treatment, the levels of CO and EF in treatment group were higher than those in control group (P < 0.05). After treatment, the levels of ESM-1 and AngII in two groups were significantly lower than before treatment, but the levels of NOS were higher than before treatment (P < 0.05). After treatment, ESM-1 and AngII levels in treatment group were lower than those in control group, but NOS levels were higher than those in control group (P < 0.05). After treatment, the levels of TAOC, AGEs, SAA, and IL-13 in two groups were significantly decreased compared with those before treatment (P < 0.05). After treatment, the levels of TAOC, AGEs, SAA, and IL-13 in treatment group were lower than those in control group (P < 0.05). Conclusion Yufeng Ningxin Dripping Pills combined with isosorbide mononitrate in treatment of angina pectoris can significantly improve the symptoms of angina pectoris, and can improve cardiac function and endothelial function, reduce oxidative stress and inflammation, and the clinical efficacy is satisfactory.

R972

内蒙古自治区卫生健康中医药(蒙医药)科技计划项目（ZMY-2024211）